Medicine and Dentistry
Antifungal Agent
14%
Batten Disease
16%
Best Corrected Visual Acuity
16%
Betaxolol
25%
Bimatoprost
54%
Bladder
50%
Brimonidine
25%
Canthus
12%
Clinical Feature
50%
COVID-19
20%
COVID-19 Vaccination
50%
Cross Sectional Study
29%
Decision Making
12%
Dermatological Agent
13%
Disease
16%
Drug Therapy
32%
Electrooculography
16%
Electroretinography
16%
Embolism
25%
Erythema
12%
Eye Disease
21%
Eye Drops
50%
Eyelid
11%
Fluorescein Angiography
12%
Fungal Endophthalmitis
50%
Gene Sequence
50%
Generic Drug
75%
Genetic Screening
16%
Glaucoma
61%
Latanoprost
29%
Macular Degeneration
50%
Medicare
100%
Microbiome
50%
Multimodal Imaging
33%
Occupation (Patient Social Context)
25%
Ophthalmology
15%
Prostaglandin Derivative
50%
Retina Blood Vessel Occlusion
50%
Retina Dystrophy
33%
RNA 16S
50%
Septicemia
14%
Subcutaneous Injection
12%
Symptom
26%
Systemic Disease
16%
Travoprost
41%
Uveitis
50%
Vascularity
12%
Visual Acuity
55%
Visual Impairment
45%
Wound Healing
12%
Keyphrases
Academy
14%
Average Price
8%
Bimatoprost
19%
Candida
14%
Clinical Features
50%
COVID-19 Spike Protein
10%
Days' Supply
16%
Dermatological Diseases
15%
Dermatologist
50%
Drug Class
17%
Drug Use
10%
Emergency Setting
7%
Emmetropes
50%
Emmetropia
7%
Excel
11%
Fungal Endophthalmitis
50%
Generic Drugs
17%
Glaucoma
50%
Glaucoma Medication
10%
Hg(p)
7%
Intraocular Pressure
50%
Intravitreal Antifungal
14%
Latanoprost
11%
Lumigan
8%
Masquerade
14%
Medicare Part D
100%
MFSD8
50%
Near Work
50%
Ophthalmologist
58%
Optical Gap
8%
Optometrist
58%
Pattern-based
50%
Prescribers
11%
Prescribing Patterns
50%
Price Variation
33%
Prostaglandin Analogs
50%
Retinal Occlusion
12%
Retrospective Longitudinal Study
8%
Risk Factors
14%
Screening Guidelines
14%
Septicemia
14%
Total Expenditure
8%
Travatan
8%
Travoprost
15%
United States
20%
Uveitis
50%
Vision Loss
12%
Visual Acuity
14%
Visual Outcome
14%
Xalatan
8%
Nursing and Health Professions
Betaxolol
7%
Bimatoprost
10%
Brimonidine
7%
Cross-Sectional Study
7%
Disease Severity
8%
Drug Therapy
16%
Drug Utilization
8%
Eye Disease
16%
Food and Drug Administration
8%
Generic Drug
57%
Glaucoma
50%
Intraocular Pressure
50%
Medicare
50%
Occupation (Patient Social Context)
7%
Ophthalmologist
100%
Optometrist
50%
Patient Preference
8%
Private Practice
8%
Travoprost
7%
Treatment Outcome
8%
